Literature DB >> 16272695

HMG-CoA reductase inhibitors do not improve glucose intolerance in spontaneously diabetic Goto-Kakizaki rats.

Kumi Satoh1, Natsue Keimatsu, Makoto Kanda, Toshinori Kasai, Akira Takaguri, Fan Sun, Kazuo Ichihara.   

Abstract

We examined whether 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) improve glucose intolerance in spontaneously diabetic Goto-Kakizaki (GK) rats or not. The fasting blood glucose, plasma insulin, and serum cholesterol levels were significantly higher in GK rats than those in age-matched Wistar rats. All rats were given orally once a day 0.5% carboxymethylcellulose, pravastatin 8 mg/kg, simvastatin 8 mg/kg, or atorvastatin 8 mg/kg. An oral glucose tolerance test (OGTT) was performed before and 3, 6 and 12 weeks after statin treatments. The hyperglycemic response to OGTT in GK rats significantly exceeded that in Wistar rats. The plasma insulin level in GK rats increased with age until 14-week-old (treated for 6 weeks), and then decreased. Glucose intake significantly increased the plasma insulin in almost all rats. The increment of plasma insulin due to OGTT in GK rats appeared to be less than that in Wistar rats, because the basal level was already high in GK rats. Pravastatin, simvastatin, and atorvastatin did not modify changes in blood glucose and plasma insulin induced by glucose intake. In conclusion, long-term treatments of GK rats with statins did not improve glucose intolerance observed during OGTT.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16272695     DOI: 10.1248/bpb.28.2092

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  6 in total

1.  Co-administration of paroxetine and pravastatin causes deregulation of glucose homeostasis in diabetic rats via enhanced paroxetine exposure.

Authors:  Feng Li; Mian Zhang; Dan Xu; Can Liu; Ze-Yu Zhong; Ling-Ling Jia; Meng-Yue Hu; Yang Yang; Li Liu; Xiao-Dong Liu
Journal:  Acta Pharmacol Sin       Date:  2014-06       Impact factor: 6.150

2.  Effect of long- and short-term treatments with pravastatin on diabetes mellitus and pancreatic fibrosis in the Otsuka-Long-Evans-Tokushima fatty rat.

Authors:  M Otani; M Yamamoto; M Harada; M Otsuki
Journal:  Br J Pharmacol       Date:  2009-12-15       Impact factor: 8.739

3.  A role for atorvastatin and insulin combination in protecting from liver injury in a model of type 2 diabetes with hyperlipidemia.

Authors:  P Matafome; E Nunes; T Louro; C Amaral; J Crisóstomo; L Rodrigues; A R Moedas; P Monteiro; A Cipriano; R Seiça
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-10-21       Impact factor: 3.000

4.  Augmented reduction of islet β-cell mass in Goto-Kakizaki rats fed high-fat diet and its suppression by pitavastatin treatment.

Authors:  Hiroki Mizukami; Wataru Inaba; Kazunori Takahashi; Keisuke Inoue; Kimio Sawanobori; Soroku Yagihashi
Journal:  J Diabetes Investig       Date:  2012-06-06       Impact factor: 4.232

5.  Energy restriction, exercise and atorvastatin treatment improve endothelial dysfunction and inhibit miRNA-155 in the erectile tissue of the aged rat.

Authors:  B Rocha; A R Rodrigues; I Tomada; M J Martins; J T Guimarães; A M Gouveia; H Almeida; D Neves
Journal:  Nutr Metab (Lond)       Date:  2018-04-16       Impact factor: 4.169

6.  A combination of nutriments improves mitochondrial biogenesis and function in skeletal muscle of type 2 diabetic Goto-Kakizaki rats.

Authors:  Weili Shen; Jiejie Hao; Chuan Tian; Jinmin Ren; Lu Yang; Xuesen Li; Cheng Luo; Carl W Cotma; Jiankang Liu
Journal:  PLoS One       Date:  2008-06-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.